AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

Non-invasive Stimulation of the Glymphatic System for Slowing Cognitive Decline

RecruitingNAAges 20 Years - 85 YearsAllUniversity of Wisconsin, Madison
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

The purpose of this research is to demonstrate that mild stimulation of a nerve (trigeminal nerve) in the head can modulate blood flow in the brain. The modulated blood flow will restore the flow of cerebrospinal fluid (CSF) and this in turn can help improve waste clearance in the brain and prevent build up that may lead to disease.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria - Healthy Participants : * Age 20-85 years * Willing and able to undergo all procedures * Free of any neurological (e.g., epilepsy, stroke, Parkinson's, brain tumors, moderate or severe traumatic brain injury), neuropsychiatric (e.g., schizophrenia, substance abuse, clinical depression), or developmental (e.g., autism, ADHD) or any other medical condition at the discretion of the PI and co-investigators Inclusion Criteria - mTBI : * Age 20-65 * Diagnosed with mild traumatic brain injury and be within 1-52 weeks post-injury * Willing and able to undergo all procedures Exclusion Criteria - Healthy Participants: * Contraindication to MRI * Known allergies to common electrode materials Exclusion Criteria - mTBI: * Contraindications for MRI * Known allergies to common electrode materials * Candidates currently on cardiovascular medications which, in the opinion of the investigators, would introduce a confounding factor to glymphatic system function (i.e. ACE-inhibitors, angiotensin receptor blockers, calcium channel blockers) * Candidates who have chronic infectious diseases (e.g. hepatitis, HIV, TB) * Candidates diagnosed with small vessel disease, vascular associated dementia (e.g. VCID), or renal disease * Candidates retinopathies or neuropathies that, in the opinion of the investigators, would prevent them from being able to complete the study or would introduce a confounding factor to glymphatic system function * Candidates with neurological disorders other than those attributed to their primary diagnosis (e.g. MS, PD, ALS, AD or other dementia, uncontrolled pain) * Candidates who have had a penetrating injury, craniotomy (with the exception of a burr hole (trephination) for resolution of acute subdural hematoma), or refractory subdural hematoma * Candidates with a history of seizures (except those in the acute or post-acute phases and are controlled) * Candidates who experienced a loss of consciousness greater than 24 hours as a result of their TBI * Candidates who, in the opinion of the investigators, are unable to feel a sensory referred sensation from the stimulation or successfully complete the electrode placement and testing fNIRs
๐Ÿ’Š

What it tests

  • Functional near-infrared spectroscopy (fNIRS)
  • V1 stimulation electrodes
  • Magnetic Resonance Imaging (MRI)
  • MAGNUS scanner
๐Ÿ“

Where

1 site
University of Wisconsin - Madison
Madison, United States
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy